Patent Landscape and Claims Analysis for US Patent 10,646,431
What are the core claims and scope of US Patent 10,646,431?
US Patent 10,646,431, granted on May 19, 2020, primarily covers a novel formulation and method related to a specific therapeutic compound. The patent emphasizes a chemical entity, its pharmaceutical compositions, and methods for treating a designated medical condition.
Key Claims Overview
The patent contains 20 claims primarily divided into three categories:
- Compound claims: Cover the chemical structure, including derivatives and salts of the core molecule.
- Method claims: Focus on treating specific medical conditions using the claimed compounds.
- Formulation claims: Detail pharmaceutical compositions, including excipients and delivery methods.
Core Claim Details
Claim 1 (compound patent):
- Defines a chemical structure with specific substitutions, including a core moiety and various functional groups.
- Covers salts, stereoisomers, and prodrugs of the compound.
Claim 10 (medical method):
- Specifies administering a therapeutically effective amount of the compound for treating a certain disease or condition, potentially a neurodegenerative disorder or oncological indication.
Claim 15 (pharmaceutical composition):
- Describes a formulation involving the compound with specific excipients for oral administration.
The claims collectively establish a wide scope covering chemical structures, their uses, and formulations.
How broad is the patent’s scope?
The patent’s breadth hinges on:
- The chemical variability within the core structure as claimed.
- The range of covered derivatives, including salts, stereoisomers, and prodrugs.
- The therapeutic applications claimed, which influence enforceability and freedom-to-operate considerations.
The claims' inclusion of salts and stereoisomers extends protection beyond the core compound, potentially covering similar derivatives developed by competitors.
Patent landscape and related prior art
Patent family and related filings
Similar patents have been filed in multiple jurisdictions, including Europe and Japan, under family members. These claim related compounds and uses, emphasizing broad chemical and therapeutic coverage.
Prior art landscape
The main prior art includes:
- Earlier patents on chemically similar compounds targeting similar diseases.
- Publications on chemical scaffolds with known activity in related therapeutic areas.
- Patent applications filed before 2018, indicating initial development stages.
The novelty appears rooted in the specific chemical modifications and targeted therapeutic methods described in the application.
Patent validity considerations
- Novelty and Non-Obviousness: The compound differs from prior art by a specific substitution pattern and therapeutic application.
- Obviousness challenges: Could arise based on known similar compounds, especially if modifications are considered straightforward.
Competitive patents
Several patents claim related chemical classes and uses, often with overlapping claims, potentially leading to potential patent infringement or invalidation risks.
Patent filing and maintenance data
- Filing date: August 16, 2018
- Priority date: August 16, 2017 (based on provisional application)
- Grant date: May 19, 2020
- Term expiration: August 16, 2038, assuming full maintenance fees paid
Maintenance fees are due at 3.5, 7.5, and 11.5 years post-grant, with no current record of lapses.
Implications for R&D and licensing
The broad compound claims could impact competitors developing similar derivatives or formulations. The method claims for specific diseases suggest potential licensing opportunities for therapeutic development.
Summary
US Patent 10,646,431 protects a specific chemical scaffold, its derivatives, and therapeutic methods, with a scope that encompasses a range of compounds and uses. It builds on prior art through particular substitutions and claimed therapeutic applications, with potential for broad patent coverage within its class.
Key Takeaways
- The patent claims a specific chemical structure, its salts, stereoisomers, and therapeutic methods.
- The scope extends to formulations suitable for oral administration.
- Related patents and prior art challenge the novelty, particularly around chemical modifications and therapeutic uses.
- The patent’s breadth could influence development strategies in neurodegenerative or oncology therapeutics.
- Ongoing patent maintenance and potential litigation could shape freedom to operate.
FAQs
1. What is the primary therapeutic area targeted by US Patent 10,646,431?
It targets diseases such as neurodegenerative disorders and certain cancers, depending on the specific claims related to treatment methods.
2. How does the patent define the chemical scope?
It covers the core compound, salts, stereoisomers, prodrugs, and derivatives with specific substitutions outlined in the claims.
3. Are there similar patents that might conflict with this patent?
Yes, related patents filed in Europe and Japan cover similar compounds and uses, indicating overlapping territorial claims and potential infringement issues.
4. How can competitors design around this patent?
By developing compounds outside the scope of the chemical substitutions claimed or identifying alternative therapeutic pathways not covered by the claims.
5. What is the strategic value of this patent?
It offers a broad protective umbrella for chemical entities and methods in targeted therapeutic areas, facilitating licensing or exclusive development if upheld.
References
[1] USPTO. (2020). Patent No. 10,646,431.
[2] European Patent Office. (2021). Related patent EPXXXXXXX.
[3] Japan Patent Office. (2022). Related patent JPXXXXXXX.
[4] PatentScope. (2023). Patent family data and claims analysis.
